Figure 4.

Biodistribution and antitumor effect of the prodrug nanoparticles in vivo. a) IVIS images of CJSP and HCJSP distribution in Panc02 tumor‐bearing mice in vivo; b) Fluorescence imaging and semi‐quantitative analysis of CJSP and HCJSP distribution in the tumor site ex vivo examined at the indicated time points; c) Experimental schedule for HCJSP‐mediated photoimmunotherapy of pancreatic cancer; d) The average and individual tumor growth curves in each experimental group (n = 5); The Panc02 tumor‐bearing C57 mice were treated with PBS, JQ1, HCP + Laser, HCJSP, or HCJSP + Laser at an identical JQ1 dose of 15 mg kg⁻¹ or PPa dose of 5.0 mg kg⁻¹; e) TUNEL staining of the tumor sections at the end of antitumor studies (blue: DAPI; red: TUNEL, scale bar = 100 µm); f) Survival curve of the Panc02‐tumor‐bearing mice following the indicated treatments; g) The average tumor growth curves in each group throughout the observation period (n = 5); h,i) Macroscopic and microscopic observation and quantitative analysis of the lung metastatic nodules of in the Pano02 tumor‐bearing mice at the end of the antitumor study. The results were expressed as mean ± s.d, *p < 0.05, **p < 0.01, ***p < 0.001).